Trial Profile
Phase II trial of fulvestrant (Faslodex) in women with metastatic breast cancer and failure on aromatase inhibitor therapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 10 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Sep 2005 New trial record.